Holen Sie sich die Stockscreener-App
13.28
4.80%
-0.67
Mesoblast Ltd Adr Aktie (MESO) Neueste Nachrichten
Mesoblast (MESO) Slips 1.68% to $14.08 as Shares Pull Back From Recent HighsSocial Sentiment - siam.in
Mesoblast (MESO) Slips 1.68% to $14.08 as Shares Pull Back From Recent HighsNAAIM Exposure - dars.gov.et
Mesoblast (NASDAQ: MESO) Secures FDA Approval for TIBA Potency Assay in Ryoncil Production - Kalkine Media
MEOBF Form 4 FilingsMESOBLAST LTD SEC Form 4 - Stock Titan
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
Mesoblast LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
Arena Pharmaceuticals Inc (ARNA) Peer Comparison – Compare with Others - Value Research
Mesoblast Limited Files Annual Form 20-F with US SEC for Fiscal Year Ended June 30, 2026 - Kalkine
Earnings call transcript: Mesoblast posts $115 million in FY2026 revenue, stock slips - Investing.com
Mesoblast (NASDAQ: MESO) gives director 875,000 incentive options - stocktitan.net
Mesoblast (MESO) Latest: Falls 2.47% to $17.00 in the Current Update; Price Levels: Support at $16.15 and Resistance at $17.85 Frame the Range for the Current SessionAnchored VWAP - careplusvn.com
Mesoblast (MESO) Latest: Falls 2.47% to $17.00 in the Current Update; Price Levels: Support at $16.15 and Resistance at $17.85 Frame the Range for the Current SessionPullback Trade - dars.gov.et
Mesoblast (MESO) Latest: Falls 2.47% to $17.00 in the Current Update; Price Levels: Support at $16.15 and Resistance at $17.85 Frame the Range for the Current SessionDonchian Channel - www.dars.gov.et
Mesoblast (MESO) Momentum: Ends Up by 1.56% at $16.93; Next Session: Price Remains Between $16.08 Support and $17.78 ResistanceLinear Regression - careplusvn.com
Mesoblast (MESO) Momentum: Ends Up by 1.56% at $16.93; Next Session: Price Remains Between $16.08 Support and $17.78 ResistanceZero Lag EMA - dars.gov.et
Mesoblast (MESO) Momentum: Ends Up by 1.56% at $16.93; Next Session: Price Remains Between $16.08 Support and $17.78 ResistanceCup and Handle - www.dars.gov.et
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment - Sahm
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Movi - Benzinga
Mesoblast Shares Jump 8.82% on ASX as Biotech Rebounds From Friday's Sharp Selloff Tied to State Street Filing - International Business Times Australia
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - tradingview.com
MESO Q1 2026 Earnings: EPS Slightly Misses Estimates on Pre-Revenue Loss, Shares Rise 2.97% - careplusvn.com
MESO Q1 2026 Earnings: EPS Slightly Misses Estimates on Pre-Revenue Loss, Shares Rise 2.97%Positive Surprise Momentum - www.dars.gov.et
Why Mesoblast (NASDAQ:MESO) Sees NASDAQ Composite Spotlight Now? - Kalkine Media
MESO Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesEarnings Revision Downgrade - careplusvn.com
MESO Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesSlow Growth Warning - dars.gov.et
MESO Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesProfit Announcement - dars.gov.et
Mesoblast Shares Decline Nearly 5% as Key Support Levels TestedComposite Profile - dars.gov.et
Mesoblast Shares Decline Nearly 5% as Key Support Levels TestedFactor ETF Flow - careplusvn.com
Mesoblast Limited (ASX:MSB) Heats Up Again as Biotech Investors Watch Its Next Move - Kalkine
Mesoblast (ASX: MSB) Slips as Investors Monitor Ryoncil Growth and Product Pipeline - Kalkine
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - TradingView
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
What Triggered Today's Move in the Mesoblast (ASX:MSB) Share Price? - Kalkine
Mesoblast (ASX:MSB) Shares Give Back Ground After a Sharp Rally - Kalkine
Daily Brief Health Care: First Wave BioPharma , NeuroSpectrum Insights, Mesoblast Ltd, Know Labs , Zoetis Inc, CTT Pharmaceutical Holdings, Oncolytics Biotech, ATAI Life Sciences NV and more - Smartkarma
Daily Brief Australia: Genesis Minerals, Perpetual Ltd, Mesoblast Ltd, BHP Group Ltd, Pacific Niugini, D3 Energy, Noble Helium and more - Smartkarma
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday - Benzinga
Why Is Mesoblast Stock Up Today? - Kalkine
Mesoblast Limited Announces ASX Quotation for 2.25 Million Shares Issued via Employee Share Option Plan - Kalkine Media
Is Mesoblast (ASX:MSB) Trading Within Its 52-Week Price Range? - Kalkine
Mesoblast Issues 2.25 Million Ordinary Shares Under Employee Share Option Plan - Kalkine
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewswire Inc.
Mesoblast reaches 300-patient enrollment in back pain trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
SK Hynix Nasdaq debut: $26.5 billion ADR listing sets record - Yahoo Finance
Mesoblast Reports Strong RYONCIL® Revenue, Exceeding Projections - Sharecafe
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 - GlobeNewswire Inc.
Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen - Barchart.com
5.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):